Cargando…

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach

Eltrombopag is a thrombopoietin receptor (MPL) agonist approved for the treatment of primary immune thrombocytopenia (ITP). Recent evidence shows that some patients may sustain platelet counts following eltrombopag discontinuation. The systemic immunomodulatory response that resolves ITP in some pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lozano, Maria L., Segú-Vergés, Cristina, Coma, Mireia, Álvarez-Roman, María T., González-Porras, José R., Gutiérrez, Laura, Valcárcel, David, Butta, Nora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269123/ https://www.ncbi.nlm.nih.gov/pubmed/34199099 http://dx.doi.org/10.3390/ijms22136907

Ejemplares similares

Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease
por: Segú-Vergés, Cristina, et al.
Publicado: (2021)

In silico clinical trial evaluating lisdexamfetamine’s and methylphenidate’s mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients’ population
por: Gutiérrez-Casares, José Ramón, et al.
Publicado: (2023)

In silico evaluation of the role of lisdexamfetamine on attention-deficit/hyperactivity disorder common psychiatric comorbidities: mechanistic insights on binge eating disorder and depression
por: Gutiérrez-Casares, José Ramón, et al.
Publicado: (2023)

Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome
por: Segú-Vergés, Cristina, et al.
Publicado: (2023)

Eltrombopag in long‐term management of pediatric thrombocytopenia
por: Shah, Sanjay J., et al.
Publicado: (2018)

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
por: Profit, Louise
Publicado: (2006)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
por: Lambert, Michele P
Publicado: (2016)

Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia
por: Maraziti, Giorgio, et al.
Publicado: (2021)

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome
por: Xu, Liping, et al.
Publicado: (2022)

Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial
por: Zaninetti, Carlo, et al.
Publicado: (2020)

Considerations in the Management of Hepatitis C Virus-related Thrombocytopenia with Eltrombopag
por: Danish, Fazal A., et al.
Publicado: (2010)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish, Fazal-i-Akbar, et al.
Publicado: (2013)

Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag
por: Tarantino, Michael D., et al.
Publicado: (2014)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
por: Özdemirkıran, Füsun, et al.
Publicado: (2015)

Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag
por: Nambiar, Vivek, et al.
Publicado: (2016)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease
por: Wang, Juan, et al.
Publicado: (2021)

Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia
por: Di Paola, Alessandra, et al.
Publicado: (2020)

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
por: Güven, Zeynep Tuğba, et al.
Publicado: (2022)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
por: Carcereny, Enric, et al.
Publicado: (2021)

Successful Eltrombopag Therapy in a Child with MYH9-Related Inherited Thrombocytopenia
por: Lassandro, Giuseppe, et al.
Publicado: (2022)

Eltrombopag Use in Thrombocytopenia for Endoscopic Submucosal Dissection of a Gastric Carcinoid
por: Kolb, Jennifer M., et al.
Publicado: (2014)

Eltrombopag Improves Refractory Thrombocytopenia in a Patient with Systemic Lupus Erythematosus
por: Shima, Natsuki, et al.
Publicado: (2018)

Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
por: Elbedewy, Tamer A, et al.
Publicado: (2019)

Successful Use of Eltrombopag in a Young Child With Chronic Immune Thrombocytopenia
por: Gruhn, Bernd, et al.
Publicado: (2021)

Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis
por: Ahmed, Hafiz Abdul Waqas, et al.
Publicado: (2021)

Eltrombopag use for refractory immune thrombocytopenia in pregnancy: A case report
por: Weingarten, Sarah J., et al.
Publicado: (2020)

Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
por: Patwardhan, Pallavi, et al.
Publicado: (2021)

Elucidation of DNA-Eltrombopag Binding: Electrochemical, Spectroscopic and Molecular Docking Techniques
por: Cheraghi, Somaye, et al.
Publicado: (2023)

Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case
por: Santoro, Cristina, et al.
Publicado: (2017)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia
por: Park, Rojin
Publicado: (2015)

A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag
por: Yoon, Jung-Ki, et al.
Publicado: (2019)

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey
por: Koca Yozgat, Ayça, et al.
Publicado: (2020)

A case of immune thrombocytopenia due to miliary tuberculosis effectively treated with eltrombopag
por: Wada, Hiroshi, et al.
Publicado: (2020)

Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia
por: Nomura, Shosaku, et al.
Publicado: (2021)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
por: Kaur, Manraj N., et al.
Publicado: (2022)

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia
por: Matsumoto, Megumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u35udbhrkc8v0ctan0smi9qtaj